CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 75% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Y-mAbs Therapeutics, Inc. - YMAB CFD

12.12
5.03%
  • Summary
  • Historical Data
Trading сonditions
Spread 0.10
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.02629 %
Charges from full value of position ($-5.00)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.02629%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.004068 %
Charges from full value of position ($0.77)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.004068%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 11.54
Open 11.56
1-Year Change 76.49%
Day's Range 11.37 - 12.15
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jul 19, 2024 11.54 -0.16 -1.37% 11.70 11.70 11.37
Jul 18, 2024 11.66 -0.85 -6.79% 12.51 12.51 11.56
Jul 17, 2024 12.54 0.20 1.62% 12.34 12.91 12.05
Jul 16, 2024 13.03 0.06 0.46% 12.97 13.34 12.97
Jul 15, 2024 12.92 0.44 3.53% 12.48 13.01 12.27
Jul 12, 2024 12.42 0.29 2.39% 12.13 13.07 12.12
Jul 11, 2024 12.03 0.50 4.34% 11.53 12.24 11.41
Jul 10, 2024 11.50 0.51 4.64% 10.99 11.50 10.87
Jul 9, 2024 11.24 0.26 2.37% 10.98 11.54 10.98
Jul 8, 2024 11.27 0.32 2.92% 10.95 11.58 10.95
Jul 5, 2024 11.36 0.23 2.07% 11.13 11.36 11.07
Jul 3, 2024 11.23 -0.06 -0.53% 11.29 11.51 11.08
Jul 2, 2024 11.33 -0.22 -1.90% 11.55 11.57 11.13
Jul 1, 2024 11.76 -0.06 -0.51% 11.82 12.23 11.75
Jun 28, 2024 12.03 -0.65 -5.13% 12.68 12.93 11.74
Jun 27, 2024 12.27 0.31 2.59% 11.96 12.45 11.50
Jun 26, 2024 12.02 -0.01 -0.08% 12.03 12.14 11.73
Jun 25, 2024 12.21 0.27 2.26% 11.94 12.32 11.60
Jun 24, 2024 12.06 0.07 0.58% 11.99 12.21 11.64
Jun 21, 2024 11.97 0.22 1.87% 11.75 11.98 11.59

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Y-mAbs Therapeutics, Inc. Company profile

About Y-mAbs Therapeutics Inc

Y-mAbs Therapeutics, Inc. is a commercial-stage clinical biopharmaceutical company. The Company is focused on the development and commercialization of novel, antibody based therapeutic products for the treatment of cancer. Its product pipeline includes DANYELZA (naxitamab-gqgk), which is a humanized monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor, or GM-CSF,for the treatment of in the bone or bone marrow stable disease to prior therapy and being evaluated for the treatment of other GD2-positive tumors. It also develops Omburtamab, which is novel murine monoclonal antibody targeting B7-H3. The Company is conducting Phase II clinical trials for the treatment of patients with first-line NB, third-line NB, and in relapsed osteosarcoma.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Y-mAbs Therapeutics Inc revenues increased 68% to $34.9M. Net loss decreased 54% to $55.3M. Revenues reflect License revenue increase of 59% to $32.9M. Lower net loss reflects Foreign Exchange Gain/LossNon-Business increase from $576K (expense) to $1.9M (income), Licensing royalties decrease of 90% to $210K (expense), Research and development - Balancing val decrease of 2% to $83.5M (expense).

Industry: Bio Therapeutic Drugs

230 Park Avenue
Suite 3350
NEW YORK
NEW YORK 10169
US

People also watch

Gold

2,399.37 Price
-0.050% 1D Chg, %
Long position overnight fee -0.0196%
Short position overnight fee 0.0114%
Overnight fee time 21:00 (UTC)
Spread 0.30

BTC/USD

68,273.15 Price
+0.580% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

US100

19,835.40 Price
+1.510% 1D Chg, %
Long position overnight fee -0.0263%
Short position overnight fee 0.0041%
Overnight fee time 21:00 (UTC)
Spread 1.8

ETH/USD

3,501.02 Price
-0.130% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

Still looking for a broker you can trust?

Join the 630,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading